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Abstract
Pulmonary  hypertension  (PH)  is  one  the  most  fatal 
complications of systemic sclerosis (SSc). The aim of the 
present study was to investigate the occurrence of PH in 
SSc patients hospitalized in Department of Rheumatology 
and Internal Diseases University Hospital of Białystok in 
years 2003-2004. PH was defined as pulmonary artery sys-
tolic pressure (PASP) higher than 35 mmHg as evaluated by 
ECHO-Doppler.
We found PH in 23 out of 53 (43%) SSc patients included 
in the study. In the majority of patients 20/23 (87%) PH coex-
isted with the presence of scleroderma lung disease as evalu-
ated by high resolution computed tomography of the lungs. 
In the remaining 3/23 (13%) patients isolated (arterial) PH 
was detected. Patients with isolated PH tend to have higher 
values of PASP (82±39.0 mmHg) than those with PH and 
interstitial lung disease (42.5±6.4 mmHg).
The results of our study indicate that PH is a frequent 
complication of SSc.
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Introduction
Systemic  sclerosis  (SSc)  is  a  systemic  connective  tissue 
disease of unknown etiology. It is characterized by immune dis-
turbances, blood vessel and endothelium damage, as well as skin 
and internal organ fibrosis. The skin, the osteoarticular, cardio-
vascular, respiratory, and digestive systems as well as the kidneys 
and the nervous system are affected. The disease is chronic and 
progressive. The kind of the internal organ involvement decides 
of the course of the disease and the fate of the patient. So far, no 
drugs modifying the course of the disease have been found [1].
Clinically,  there  are  diffuse  systemic  sclerosis  (dSS)  and 
limited  systemic  sclerosis  (lSS)  –  earlier  known  as  CREST 
(Calcinosis,  Raynaud’s  phenomenon,  Esophageal  dysmotility, 
Sclerodactyly, Telangiectasia) distinguished.
One of the most serious organ complications in the course 
of the SSc is the pulmonary hypertension (PH), which signifi-
cantly increases mortality rate among the patients.
As far as pathogenesis is concerned, patients with the SSc 
reveal arterial PH, known also as isolated PH, which is charac-
terized by obliterative changes of pulmonary arteries and forms 
of secondary PH. The latter may occur due to lung parenchyma 
damage in the course of the interstitial lung disease (lung fibro-
sis), left ventricular failure or thrombo-embolic changes [2,3].
 Arterial PH usually concerns patients with limited SSc. It 
appears after a prolonged duration of the disease and is a result 
of the narrowing of pulmonary arteries. The appearance of the 
right heart failure (cor pulmonale) in patients with limited SSc 
correlates with nRNP antibody presence in serum. The rate of 
isolated  PH  occurrence  is  approximately  10-15%  of  patients 
[4,5,6].
Secondary  pulmonary  hypertension  develops  most  fre-
quently due to interstitial lung fibrosis and can occur in both dif-
fuse and limited forms of the SSc. The former reveals interstitial 
pulmonary fibrosis and PH already in the early stage of the dis-
ease. PH is secondary to interstitial pulmonary fibrosis as a  re-
sult of damage of lung tissues supporting blood vessels as well as 
the destruction of the vessels themselves. Hypoxia additionally 
strengthens hypertension due to reflex blood vessel contraction. 
According to various data, secondary pulmonary hypertension 
concerns more than 50% of patients with SSc [4,6].
Raynaud’s pulmonary phenomenon is also taken into con-
sideration in the pathogenesis of the pulmonary hypertension. 
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Patients with the SSc often present ischemic heart disease and 
myocardial perfusion disorders that can contribute to the left-
sided heart failure and subsequent increase in the pressure in 
the lung vasculature [3].
The aim of our study was to evaluate pulmonary hyperten-
sion occurrence rate in patients with SSc hospitalized in The 
Department  of  Rheumatology  and  Internal  Diseases,  Medi-
cal University of Białystok in years 2003-2004. Moreover, we 
attempted to determine clinical characteristics of patients with 
PH in the course of SSc.
Material and methods
The study was conducted in the group of 53 patients with 
diagnosed SSc, based on ARA classification criteria of 1980 [7], 
hospitalized in The Department of Rheumatology and Internal 
Diseases, University Hospital of Białystok in years 2003-2004. 
The clinical evaluation included sex, age, disease duration, dis-
ease subset, high resolution computed tomography (HRCT) of 
the lungs, pulmonary function tests and Doppler-echocardiog-
raphy (ECHO). The patients were divided into 2 groups: those 
with the limited form of SSc and those with the diffuse one. All 
patients underwent serological examinations.
The  indirect  immunofluorescence  test  for  antinuclear 
antibodies (ANA) and anticentromere antibodies (ACA) was 
performed and the presence of antibodies against topoisomer-
ase I (anti-Scl-70) was evaluated with ELISA method. Patients’ 
physical efficiency was assessed with the 6-minute-walk test. The 
pulmonary function tests (spirometry) were done in all patients. 
The presence of the interstitial lung disease was evaluated on 
the basis of HRCT of the lungs. Changes in lung tissue, visible 
in radiograms, were classified as without fibrotic features – the 
presence of so-called “ground glass” and as advanced fibrosis 
– the presence of so-called “honey combing” [8].
Pulmonary  hypertension  was  evaluated  using  Doppler-
echocardiography  (ECHO).  The  examination  was  performed 
in  a   typical  way,  according  to  The  American  Society  of 
Echocardiography instructions, with the apparatus Sonos 5500 
using  transthoracic  transducer  with  a  harmonic  resolution 
1.6-3.2 MHz.  The  systolic  pressure  in  the  pulmonary  artery 
(pulmonary artery systolic pressure, PASP) was assessed based 
on the measurement of the maximum speed of the recoil wave 
of the tricuspid valve insufficiency. Then, the gradient of right 
ventricle/right  atrium  systolic  pressure  was  calculated  in  the 
Bernoulli equation. The systolic pressure in the right ventricle, 
which is equal to the systolic pressure in the pulmonary artery 
(with lack of the pulmonary artery valvular stenosis), was calcu-
lated by adding the gradient value to the value of the right atrium 
pressure. The values above 35 mmHg of the PASP denoted the 
pulmonary hypertension (according to WHO) [9].
Statistical analysis
Statistical analysis was performed using the Mann-Whitney 
U test and the Fisher’s exact test. P values less than 0.05 were 
considered statistically significant.
Results 
In the whole group of 53 patients with SSc, the PH was 
diagnosed in 23 (43%) patients while the remaining 30 (57%) 
patients did not present features of the PH.
Twenty out of 53 SSc patients revealed the PH coexisting 
with the interstitial pneumonia confirmed by the HRCT exami-
nation. The presence of the PH without coexisting interstitial 
pneumonia and hemodynamically significant left ventricle insuf-
ficiency was observed in 3/53 (6%) patients. Thus, the isolated 
PH was diagnosed in those patients.
Altogether, 35 out of 53 SSc patients had features of inter-
stitial lung disease in the HRCT. In the whole group of SSc 
patients “ground glass” changes only were seen in the HRCT 
examination in 11 patients while the remaining 24 patients pre-
sented features of lung fibrosis.
HRCT revealed features of interstitial lung disease in 15/30 
(50%) patients without the PH. The remaining 15/30 patients 
without PH had no changes in the HRCT.
Antinuclear  antibodies  (ANA)  were  found  in  all  SSc 
patients and 22 (41%) patients had anti-topoisomerase I anti-
bodies (anti-Scl-70). ACA were present in 8 (15%) patients, all 
with the diagnosed limited form of SSc. Tab. 1 shows the general 
characteristics of 53 examined patients. 
The mean duration of the disease in a group of 20 patients 
with PH and interstitial lung disease was 15±10 years with the 
mean age of the patients 55±12 years. Clinical evaluation of the 
physical efficiency based on the 6-min-walk test in that group of 
patients was mean 353±143 meters. The mean value of PASP 
in these subjects was 42.5±6.4 mmHg while their forced vital 
capacity (FVC) was 78.4±13.6% of predicted. Anti-Scl-70 anti-
body presence was observed in 11 out of 20 patients (55%) and 
ACA – only in 1 patient (5%).
Eleven patients out of 20 (55%) with the PH and interstitial 
Table  1.  Clinical  characteristics  of  the  patients  with  systemic 
sclerosis
Sex F/M no. (%) 51\2 (97/3)
Patients age (years) * 51 ± 14 
Disease duration (years)* 13 ± 10 
Disease subset
dSSc no. (%) 15 (28)
lSSc no. (%) 38 (72)
PH(+)/PH (–) no. (%) 23/30 (43/57)
HRCT(+)/HRCT(–) no. (%) 35/18 (66/34)
ANA(+) no. (%) 53 (100)
Scl-70(+)/Scl-70(–) no. (%) 22/31 (41/59)
ACA(+)/ACA(–) no. (%) 8/45 (15/85)
HRCT(+) ground glass no. (%) 11 (20)
HRCT(+) honey combing no. (%) 24 (45)
*  values are expressed as mean ±SD
HRCT(+)=high resolution computed tomography findings consis-
tent  with  SLD;  SLD=scleroderma  lung  disease;  PH=pulmonary 
hypertension;  ANA=antinuclear  antibodies;  anti-Scl-70=anti-
topoisomerase I antibodies; ACA=anticentromere antibodies; lSSc 
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pneumonia had the diffuse form of SSc and the remaining 9/20 
(45%) had the limited SSc (Tab. 2).
The PH without changes in the lung tissue (normal results of 
HRCT examination) was observed in 3 cases out of 53 subjects 
studied. In these 3 patients isolated PH (arterial PH) was diag-
nosed. Although the group was small its clinical differentiation 
was  characteristic.  The  mean  age  was  53±11 years  while  the 
duration  of  the  disease  17±7 years.  The  6-minute-walk  test 
was on average 212±207 meters. The mean value of PASP was 
82±39 mmHg and FVC (Forced Vital Capacity) – 92±15.6%. 
Anti-Scl-70 antibodies were not found in any of these 3 patients 
and 1 person (33%) had positive ACA. The other 2 patients 
(67%) had ANA antibodies. All the patients suffered from the 
limited form of the SSc (Tab. 2 and 3).
The  mean  age  of  the  patients  without  the  PH  was 
49±15 years and the duration of the disease was 12±9 years. The 
mean test of the 6-minute-walk was 428±102 meters, and FVC 
was 92.0±15.8%. The majority of patients of this group did not 
reveal the tricuspid valve insufficiency, which prevented PASP 
measurement. Only 3 out of 30 patients presented a recoil wave 
of PASP values below 35 mmHg (mean 32±1.7 mmHg) through 
the tricuspid valve. Anti-Scl-70 antibodies were observed in 10 
out of 30 patients (33%) while ACA – in 5/30 subjects (17%). 
The diffuse form of the SSc was diagnosed in 20 patients (67%) 
and the limited form – in 10 patients (33%) (Tab. 2).
The  statistical  analysis  did  not  show  any  significant  dif-
ferences among the three groups of PH patients as far as the 
tolerance  of  physical  effort  is  concerned  (the  6-minute-walk 
test).  However,  low  tolerance  of  physical  effort  of  patients 
with isolated PH (p=0.07), as compared to those without the 
PH, should be noticed. It seems that lack of distinct statistical 
difference may occur due to small number of patients with the 
isolated PH.
FVC varied markedly between the groups of patients with-
out the PH and those with the PH and interstitial lung disease 
(p=0.002), values statistically significant.
Discussion
As a result of our observation we can state that in the group 
of 53 patients with the SSc, most patients with the PH in the 
course of systemic sclerosis reveal the interstitial lung disease. 
It concerns both forms of the SSc: the limited and diffuse ones. 
In our study, the PH patients showed a predominance of Scl-70 
antibodies.
The PH occurs frequently in patients with the SSc, even 
more than 50% of examined subjects can suffer from it. It is 
confirmed by the literature, where in the course of the diffuse 
SSc, the PH (as a result of the interstitial lung disease – second-
ary PH) occurs in up to 80% of patients [6,10,11]. The isolated 
(arterial) PH is observed mainly in the group of patients with 
the limited form of the SSc (approximately 10% of patients) as 
well as with the presence of ACA [5,6,12]. Our study presents 
similar results. The patients with the isolated PH constituted 
a   small  3-person  group  (6%)  with  a  differentiated  clinical 
Table 2.  Comparison of of patients with and without PH
PH(+), HRCT(+) PH(+), HRCT(–) PH(–)
Number of patients (%) 20 (37) 3 (6) 30 (57)
Age (years) * 55±12  53±11  49±15 
Disease duration (years) * 15±10  17±7  12±9 
6-min-walk test (meters) * 353±143 212±207  428±102 
PASP (mmHg) * 42.5±6.4  82.0±39.0 (N=3) 32.0±1.7
FVC (% of predicted) * 78.4±13.6  92.0±15.6 92.0±15.8 
ANA no. (%) 20 (100) 3 (100) 30 (100)
Scl-70(+)/Scl-70(–) no. (%) 11/9 (55/45) 0 0 10/20 (33/67)
ACA(+)/ACA(–) no. (%) 1/19 (5/95) 1/2 (33/67) 5/25 (17/83)
Disease subset
dSSc no. (%) 11 (55) 0 0 20 (67)
lSSc no. (%) 9 (45) 3 (100) 10 (33)
*  values are expressed as mean±SD; PH=pulmonary hypertension; PASP=pulmonary artery systolic pressure; FVC-forced vital capacity; HRCT 
– high resolution computed tomography; ANA=antinuclear antibodies; Scl-70=anti-topoisomerase I antibodies; ACA=anticentromere antibod-
ies; lSSc – limited systemic sclerosis; dSSc – diffuse systemic sclerosis
Table 3.  Clinical characteristics of the patients with isolated PH
Patients with isolateded PAH
Age/years Disease duration Disease subset antibodies PASP mmHg 6-min.-walk test FVC (%)
1 66 25 lSSc ANA 110 110 m 84
2 47 16 lSSc ACA 37 450 m 110
3 46 11 lSSc ANA 99 75 m 82
PAH=pulmonary arterial hypertension; PASP=pulmonary artery systolic pressure; FVC=forced vital capacity; ANA=antinuclear antibodies; 
ACA=anticentromere antibodies; lSSc=limited systemic sclerosis; dSSc=diffuse systemic sclerosis300 Gińdzieńska-Sieśkiewicz E, et al.
course of the limited SSc. In this group the values of the PASP 
tend to be higher than in the group with the PH and interstitial 
lung disease. The physical efficiency of these patients was also 
lower than in the patients with PH and interstitial lung disease 
(the 6-  min-walk test, mean 212±207 m as compared to mean 
353±143 m). Other authors [5,12] also observed a similar clini-
cal course.
It seems that the examined by us cases are the group of 
patients with the advanced form of the disease. Only few early 
stages of the PH are detected in the course of the SSc. It is 
probably due to early asymptomatic course of the PH, which 
afterwards  gives  symptoms  of  effort  tolerance  lowering  and 
dyspnoea [4,6].
Pulmonary and cardiovascular complications appear most 
frequently in the first years of diffuse SSc. Therefore, patients 
should be under thorough control as far as organ complication 
occurrence is concerned [5,10]. The golden mean of diagnosis of 
PH is considered to be the right heart catheterization. However, 
it is an invasive examination and available only in highly special-
ized  centers  [3].  There  were  many  studies  performed  which 
showed  that  ECHO  examination  with  Doppler  method  is  as 
much effective in evaluation of the PH as the catheterization. 
On the other hand, it is less accurate as there is lack of the recoil 
wave  through  the  pulmonary  arterial  valve,  which  prevents 
a   detailed  evaluation  but  the  ECHO  examination  provides 
additional information about the structure and function of the 
heart  muscle  [4,13,14].  The  ECHO  examination  is  nowadays 
considered  as  the  screening  of  the  PH  in  patients  with  the 
systemic sclerosis and as such should be conducted every year to 
enable introducing an early therapy of the PH [9,13].
The PH is an important diagnostic and therapeutic problem 
in patients with the SSc. In case of the limited SSc, a special 
attention should be paid to the presence of isolated arterial PH, 
which occurs usually after several years of the onset and can be 
characterized by a dramatic course due to high values of the pul-
monary arterial pressure, deteriorating physical efficiency of the 
patients and lack of fully effective therapy. The PH secondary 
to the interstitial lung disease frequently occurs both in patients 
with diffuse and limited SSc [9]. Thus, it is necessary to perform 
early diagnostics to detect the PH (ECHO) in each patient who 
is suspected of suffering from an interstitial lung disease based 
on the spirometric examination [8]. It would allow to introduce 
early therapy of both lung fibrosis and PH in such patients.
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